FOX04-DRI

InvestigationalSenolytic ResearchLongevity & cellularImmune & gut
4.1

Caution, BioHarmony verdict

BioHarmony score 4.1 out of 10

FOXO4-DRI is a designed senolytic peptide that kills senescent cells by breaking the FOXO4 to p53 bond, famous for restoring fur and kidney function in aged mice per Baar 2017. It has zero human trials, no registered study, and grey-market-only sourcing, so it scores 4.0-4.5/10 in Caution.

Read full report

What is FOX04-DRI?

FOXO4-DRI is a designed senolytic peptide that kills senescent cells by breaking the bond between the protein FOXO4 and the tumor suppressor p53, and it scores 4.0-4.5/10 in Caution for one blunt reason: it is one of the most hyped longevity peptides on the market and it has zero human evidence. The mechanism is genuinely clever and the preclinical result is striking, but every bit of that result is in mice or cell culture, led by a single 2017 study in Cell, per Baar 2017.

From the BioHarmony report, reviewed Sep 19, 2026.

Saved on this device only.

How it is thought to work

Senolysis: displaces FOXO4 from p53 to push senescent cells into apoptosis

Safety watch-outs

  • Any active or suspected cancer: do not use, since broad p53 and apoptosis modulation in an uncharacterized peptide is exactly the wrong…
  • Fever, spreading redness, or pus at an injection site (possible infection from non-sterile research-chemical product): stop and seek…
  • Any unexplained systemic reaction after injection of an unapproved grey-market peptide: stop and consult a clinician.

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

No approved-label or study protocol is recorded for FOX04-DRI yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (2)

Attributed viewpoints, separate from primary research.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalInvestigational
CompoundingEligibility not established.

FOXO4-DRI remains preclinical. Published studies report senescent-cell effects in cell and mouse models; they do not establish human safety, effectiveness, or dosing.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.